title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Tuesday,20220524T161351,https://www.benzinga.com/markets/options/22/05/27375519/52-weeks-high-and-low-article,ITOS,0.010175,Neutral,0.007326
99 Biggest Movers From Yesterday,20220512T082956,https://www.benzinga.com/news/22/05/27156577/99-biggest-movers-from-yesterday,ITOS,0.042462,Neutral,-1.5e-05
"Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings - Dnow  ( NYSE:DNOW ) , Evolv Technologies  ( NASDAQ:EVLV ) ",20240510T140059,https://www.benzinga.com/news/24/05/38761518/dow-jumps-over-100-points-dnow-posts-downbeat-earnings,ITOS,0.151064,Somewhat-Bullish,0.217071
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,ITOS,0.020404,Neutral,0.078882
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",20230925T210100,https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,ITOS,0.018757,Neutral,0.024665
